We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
- Authors
Choi, In Sil; Choi, Mihong; Lee, Ju Hyun; Kim, Jee Hyun; Suh, Koung Jin; Lee, Ji Yun; Kang, Beodeul; Kim, Ji-Won; Kim, Se-Hyun; Kim, Jin Won; Lee, Jeong-Ok; Kim, Yu Jung; Bang, Soo-Mee; Lee, Jong Seok; Lee, Keun-Wook
- Abstract
Purpose: There is limited data on third-line chemotherapy in patients with metastatic gastric cancer (MGC). This study was conducted to assess third-line treatment patterns, outcomes, and clinical parameters related to survival outcomes in patients with MGC. Methods: Using the Korean Health Insurance Review and Assessment Service (HIRA) database, a nationwide population-based outcomes study was conducted. From the HIRA database, patients newly diagnosed in 2010 with MGC were identified (N = 1,871), and of these, 229 patients who had received third-line chemotherapy were finally selected for this study. Results: Prior to third-line chemotherapy, more than 90% of patients received fluoropyrimidine and platinum, and 43.7% and 40.6% received taxane and irinotecan, respectively. Various third-line chemotherapy regimens containing taxane (docetaxel or paclitaxel), irinotecan, or oxaliplatin were prescribed. The median overall survival (OS) of all patients receiving third-line chemotherapy was 4.4 months. The median time from the start date of first-line chemotherapy to the start date of third-line chemotherapy (TF1T3) was 9.5 months, and a longer TF1T3 was the only factor that was significantly associated with an increased OS. The median OS of patients who had received fluoropyrimidine, platinum, and taxane followed by third-line irinotecan-based therapy was similar to that of patients who had received fluoropyrimidine, platinum, and irinotecan followed by third-line taxane-based therapy (p = 0.894). Conclusion: In patients with MGC receiving third-line chemotherapy, TF1T3 was the only significant factor associated with OS. The sequence of using taxane and irinotecan as subsequent therapy after first-line failure was not shown to impact survival outcome.
- Subjects
STOMACH cancer; HEALTH insurance; CANCER chemotherapy; IRINOTECAN; FLUOROPYRIMIDINES
- Publication
PLoS ONE, 2018, Vol 13, Issue 6, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0198544